Table 7.

Completed clinical trials for the use of pralsetinib, cabozantinib, vandetanib, or selpercatinib.

Title and NCT Number	Design	Recruitment Status
An international, randomized, double-blinded, phase 3 efficacy study of XL184 versus placebo in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (NCT00704730)	A phase III, randomized, double-blinded study	Completed
Molecular profile of metastatic sporadic medullary thyroid cancer (sMTC) patients and possible correlation with vandetanib therapy (NCT02268734)	Observational study	Completed
European, observational, prospective study to evaluate the benefit/risk of vandetanib in RET mutation negative and positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic medullary thyroid cancer (NCT01945762)	Observational study	Completed
A phase I/II, open-label study to evaluate the safety and tolerability of vandetanib 300 mg/Day in Japanese patients With unresectable locally advanced or metastatic medullary thyroid carcinoma (NCT01661179)	A phase I/II, open-label study	Completed
CAPRELSA®® REGISTRY: a Belgian registry to evaluate the use of vandetanib (Caprelsa®®) in current clinical practice (NCT02109250)	Observational study	Completed
Effectiveness of Risk minimization interventions for vandetanib in Canada (NCT01757470)	Observational study	Completed
A Phase I, randomized, open-label, single-center study to assess the pharmacokinetics of vandetanib (CAPRELSA) in healthy subjects when a single oral dose of vandetanib 300 mg is administered alone and in combination with omeprazole or ranitidine (NCT01539655)	A phase I, randomized, open-label study	Completed

Only accounting studies on adults.